GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy
Journal of Cachexia, Sarcopenia and Muscle · 2025
DOI: 10.1002/jcsm.13715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Stephen E Flaherty und 14 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Mitochondrial Myopathies, Muscular Atrophy, Exercise Tolerance. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Primary mitochondrial myopathies (PMMs) are disorders caused by mutations in genes encoding mitochondrial proteins and proteins involved in mitochondrial function. PMMs are characterized by loss of muscle mass and strength as well as impaired exercise capacity. Growth/Differentiation Factor 15 (GDF15) was reported to be highly elevated in PMMs and cancer cachexia. Previous studies have shown that GDF15 neutralization is effective in improving skeletal muscle mass and function in cancer cachexia. It remains to be determined if the inhibition of GDF15 could be beneficial for PMMs. The purpose of the present study is to assess whether treatment with a GDF15 neutralizing antibody can alleviate muscle atrophy and physical performance impairment in a mouse model of PMM.
Methods
The effects of GDF15 neutralization on PMM were assessed using Polg D257A/D257A (POLG) mice. These mice express a proofreading‐deficient version of the mitochondrial DNA polymerase gamma, leading to an increased rate of mutations in mitochondrial DNA (mtDNA). These animals display increased circulating GDF15 levels, reduced muscle mass and function, exercise intolerance, and premature aging. Starting at 9 months of age, the mice were treated with an anti‐GDF15 antibody (mAB2) once per week for 12 weeks. Body weight, food intake, body composition, and muscle mass were assessed. Muscle function and exercise capacity were evaluated using in vivo concentric max force stimulation assays, forced treadmill running and voluntary home‐cage wheel running. Mechanistic investigations were performed via muscle histology, bulk transcriptomic analysis, RT‐qPCR and western blotting.
Results
Anti‐GDF15 antibody treatment ameliorated the metabolic phenotypes of the POLG animals, improving body weight (+13% ± 8%, p < 0.0001), lean mass (+13% ± 15%, p < 0.001) and muscle mass (+35% ± 24%, p < 0.001). Additionally, the treatment improved skeletal muscle max force production (+35% ± 43%, p < 0.001) and exercise performance, including treadmill (+40% ± 29%, p < 0.05) and voluntary wheel running (+320% ± 19%, p < 0.05). Mechanistically, the beneficial effects of GDF15 neutralization are linked to the reversal of the transcriptional dysregulation in genes involved in autophagy and proteasome signalling. The treatment also appears to dampen glucocorticoid signalling by suppressing circulating corticosterone levels in the POLG animals.
Conclusions
Our findings highlight the potential of GDF15 neutralization with a monoclonal antibody as a therapeutic avenue to enhance physical performance and mitigate adverse clinical outcomes in patients with PMM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, USA.
- Obesity and Complications, Eli Lilly, Boston, Massachusetts, USA.
- Diabetes, Obesity and MASH, Global Drug Discovery, Novo Nordisk, Lexington, Massachusetts, USA.
- Program Mamager, Preclinical Sciences, Toxicology, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
- Biostatistics, Early Clinical Development, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, USA.
- Inflammation and Immunology Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, USA.
ORCID-Profile: Zhidan Wu
Zitieren
APA
Flaherty, S. E., Song, L., Albuquerque, B., Rinaldi, A., Piper, M., Shanthappa, D. H., Chen, X., Stansfield, J., Asano, S., Pashos, E., Ross, T. T., Jagarlapudi, S., Sheikh, A., Zhang, B., & Wu, Z. (2025). GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13715
Vancouver
Flaherty SE, Song L, Albuquerque B, Rinaldi A, Piper M, Shanthappa DH, et al. GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.13715
BibTeX
@article{Flaherty2025,
author = {Flaherty, Stephen E and Song, LouJin and Albuquerque, Bina and Rinaldi, Anthony and Piper, Mary and Shanthappa, Dinesh Hirenallur and Chen, Xian and Stansfield, John and Asano, Shoh and Pashos, Evanthia and Ross, Trenton Thomas and Jagarlapudi, Srinath and Sheikh, Abdul and Zhang, Bei and Wu, Zhidan},
title = {GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2025},
doi = {10.1002/jcsm.13715}
}
EUVIMED